Izpisua Belmonte, PhD, Altos Labs, advocates a disease-agnostic approach, but first, he said, “we must understand the mechanism, something that is core to the cell.” ...

System MarketThe global Mesenchymal Stem Cells Market is valued at USD 3.82 Billion in 2024 and is projected to reach a value of USD 9.08 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

Mesoblast Limited ( ($AU:MSB) ) has issued an update. Mesoblast Limited reported a significant 66% increase in revenue for its product Ryoncil, ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...

Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This ...

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company ...

The MSC market offers significant opportunities in regenerative medicine, cosmeceuticals, and cultured meat production. Leveraging their regenerative and immuno-evasive properties, MSCs are key in ...

Mesoblast Limited ( (AU:MSB) ) has shared an announcement.